The history and future of chemotherapy for melanoma Journal Article
| Authors: | Yang, A. S.; Chapman, P. B. |
| Article Title: | The history and future of chemotherapy for melanoma |
| Abstract: | Melanoma is considered a chemotherapy-resistant cancer, but in reality there are several chemotherapy drugs with significant single-agent activity. Response rates to combination regimens are reproducibly higher than with standard dacarbazine, but of the randomized trials comparing combination regimens with dacarbazine, none were of sufficient size to detect a realistic effect on survival. Similarly, adjuvant chemotherapy has not had a realistic test in melanoma. Response to chemotherapy is associated reproducibly with better survival rates suggesting that regimens with higher response rates are needed. Recent observations suggest that combining antiangiogenic agents with either dacarbazine or temozolomide can double response rates. These combinations are worthy of further investigation and might serve as a foundation on which to build a combination regimen that improves overall survival in metastatic melanoma patients. © 2009 Elsevier Inc. All rights reserved. |
| Keywords: | cancer chemotherapy; treatment outcome; survival analysis; hydroxyurea; thalidomide; clinical trial; drug activity; fatigue; neutropenia; review; sorafenib; cisplatin; doxorubicin; area under the curve; cancer combination chemotherapy; drug efficacy; drug potentiation; drug safety; side effect; antineoplastic agents; alpha interferon; paclitaxel; cancer adjuvant therapy; chemotherapy, adjuvant; temozolomide; topotecan; drug megadose; glioma; alpha2b interferon; bcg vaccine; carboplatin; dacarbazine; low drug dose; melanoma; metastasis; multiple cycle treatment; bone marrow suppression; blood toxicity; mucosa inflammation; thrombocytopenia; antineoplastic combined chemotherapy protocols; peripheral neuropathy; randomized controlled trials as topic; combination chemotherapy; melphalan; carmustine; ifosfamide; lomustine; vinblastine; docetaxel; irinotecan; drug hypersensitivity; gastrointestinal toxicity; myeloablative conditioning; drug mechanism; clinical trials, phase iii as topic; thromboembolism; glioblastoma; brain metastasis; bleomycin; tamoxifen; forecasting; vindesine; nitrosourea; drug therapy; angiogenesis inhibitors; multicenter studies as topic; fluid retention; fotemustine; autologous bone marrow transplantation |
| Journal Title: | Hematology/Oncology Clinics of North America |
| Volume: | 23 |
| Issue: | 3 |
| ISSN: | 0889-8588 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2009-06-01 |
| Start Page: | 583 |
| End Page: | 597 |
| Language: | English |
| DOI: | 10.1016/j.hoc.2009.03.006 |
| PUBMED: | 19464604 |
| PROVIDER: | scopus |
| PMCID: | PMC3904102 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 30 November 2010" - "CODEN: HCNAE" - "Source: Scopus" |
